<DOC>
	<DOCNO>NCT01865474</DOCNO>
	<brief_summary>This prospective , double-blind , randomize , control study . The investigational product , DLBS1033 dose 490 mg thrice daily placebo , give 8-week course therapy . DLBS1033 effectively demonstrate fibrinolytic , fibrinogenolytic well antithrombotic activity . Hypercoagulation state high fibrinogen level usually find diabetes mellitus patient . Therefore , hypothesis interest study DLBS1033 reduce fibrinogen level diabetes mellitus patient well Control Group .</brief_summary>
	<brief_title>Efficacy Safety DLBS1033 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>There 2 group treatment , consist 68 subject , treatment regimen follow : Treatment I : DLBS1033 bioactive fraction tablet @ 490 mg , three time daily . Treatment II : Placebo tablet DLBS1033 , three time daily . Clinical examination evaluate efficacy investigational drug perform baseline every follow-up visit ( interval 4 week ) 8 week study period . All subject advise follow lifestyle modification throughout study period . All subject direct supervision medical doctor study period . During study period , anti-diabetes treatment take study subject still continue . Other treatment related subject ' concomitant illness , hypertension , and/or dyslipidemia , allow subject ' participation study . Other medication anti-platelets , fibrinolytic agent anti-coagulants , treatment include herbals/alternatives may affect haemostatic system , allow use study period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus A1c &gt; 7.0 % Screening . Men woman , 2565 year age . Have treat lifestyle intervention and/or oral antidiabetic agent and/or insulin . Adequate liver function : ALT AST ≤ 2.5 time upper limit normal . Adequate renal function : serum creatinine &lt; 2.0 time upper limit normal . Able take oral medication . 1 . For female childbearing potential : Pregnancy , breastfeeding , intention become pregnant . Patients must accept pregnancy test trial menstrual cycle miss . Fertile patient must use reliable effective contraceptive . 2 . The presence clinically significant electrocardiographic abnormality 3 . History acute coronary syndrome ( myocardial infarction , stroke , unstable angina pectoris ) , peripheral arterial disease , venous thromboembolism cardiovascular event . 4 . History arteriosclerotic disease necessitate medical pharmacological treatment . 5 . Severe hypertension ( systolic blood pressure ≥ 180 mm Hg , diastolic ≥ 110 mm Hg ) . 6 . Treatment antiplatelets antithrombotic agent , include oral lumbrokinase product within 14 day prior Screening . 7 . Subjects prior experience DLBS1033 . 8 . Subjects highrisk bleed 9 . Presence malignancy observe clinically anamnesis . 10 . Subjects disease state , include chronic acute systemic infection , uncontrolled illness , judge investigator , could interfere trial participation trial evaluation . 11 . Subjects know suspect allergy study medication similar product . 12 . Subjects concurrent herbal ( alternative ) medicine food supplement suspect effect primary efficacy endpoint . 13 . Subjects enrol another experimental ( interventional ) protocol within past 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>DLBS1033 , Type 2 DM , fibrinolytic , hypercoagulation</keyword>
</DOC>